Special Issue

Innovative Drug Delivery and Mitochondrial-Targeted Therapies

Message from the Guest Editors

We are excited to invite you to contribute to an upcoming special issue of Pharmaceuticals on "Innovative Drug Delivery and Mitochondrial-Targeted Therapies." As the editor, it is my honor to present this initiative, which aims to gather the latest and most promising research in a field with immense therapeutic potential. The core objective of this Special Issue is to highlight and disseminate novel drug formulations and delivery strategies specifically targeting mitochondria. We aim to explore how these innovations can positively impact various pathologies where mitochondrial dysfunction plays a crucial role in disease progression and therapeutic response.

Research in mitochondrial-targeted therapies is growing exponentially, offering new perspectives for treating neurodegenerative, cardiovascular, metabolic diseases, cancer, and many other conditions.

We strongly encourage all researchers and working groups to submit their original articles and comprehensive reviews that align with the theme of this Special Issue. Your contributions will be crucial in enriching collective knowledge and accelerating the development of new therapeutic options.

Guest Editors

Dr. José Antonio Jara Sandoval Facultad de Odontología, Universidad de Chile, Santiago, Chile

Dr. Alfredo E. Molina-Berríos

Facultad de Odontología, Universidad de Chile, Santiago, Chile

Deadline for manuscript submissions

30 April 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/250201

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

